Skip to main content
IDWeek 2024 Main banner
Icon Legend
This session is not in your schedule.
This session is in your schedule. Click again to remove it.
Presentation Icons
Live Streamed
Live Streamed
On Demand
On Demand
Back

Session: Late Breaker Abstract Session: What's Going Viral

575 - Safety and Immunogenicity of mRNA-1403, a Multivalent Norovirus mRNA Vaccine, in Healthy Adults: Interim Results of a Phase 1/2, Randomized, Observer-Blind, Placebo-Controlled, Dose-Ranging Trial

Saturday, October 19, 2024
1:45 PM – 1:57 PM US PT
Location: 403 A
Disclosure(s):
Till Schoofs, MD: Moderna, Inc: Employee, Stocks/Bonds (Public Company)
Brooke A. Bollman, PhD: Moderna, Inc: Employee, Stocks/Bonds (Public Company)
Kevin Mancini, MS: Moderna, Inc: Employee, Stocks/Bonds (Public Company)
Wenlin Yuan, MS, PhD: Moderna, Inc: Employee, Stocks/Bonds (Public Company)
Lauren Bailey, PhD: Moderna, Inc: Employee, Stocks/Bonds (Public Company)
Tin Bartholomew, MA: Moderna, Inc: Employee, Stocks/Bonds (Public Company)
Esther Levine, MD: Moderna, Inc: Employee, Stocks/Bonds (Public Company)
Katherine B. Carlson, PhD, MPH: Moderna, Inc: Employee, Stocks/Bonds (Public Company)
Alexander Rumyantsev, MD, PhD: Moderna, Inc: Employee, Stocks/Bonds (Public Company)
Meklit Workneh, MD, MPH: Moderna, Inc: Employee, Stocks/Bonds (Public Company)
Doran Fink, MD, PhD: Moderna, Inc: Employee, Stocks/Bonds (Public Company)
Jaap Oostendorp, PhD: Moderna, Inc: Employee, Stocks/Bonds (Public Company)